New registry tracks COVID drug safety for pregnant women and their babies

NCT ID NCT05013632

Recruiting now Knowledge-focused Sponsor: Pregistry Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This registry is following 2,000 pregnant women who took antiviral drugs or monoclonal antibodies for COVID-19. Researchers will compare their pregnancy and baby outcomes to those who did not receive these treatments. The goal is to better understand the safety of these medications during pregnancy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: antiviral drugs (remdesivir, molnupiravir) and monoclonal antibodies (casirivimab/imdevimab, sotrovimab)
What this could lead to: If successful, this registry could provide crucial safety data on COVID-19 treatments during pregnancy, helping doctors make informed decisions.
What could go wrong: This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results may take years and depend on accurate reporting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID19

Contacts and locations

Locations

Pregistry
RECRUITING

Los Angeles, California, 90045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.